Real-time Estimate
Cboe BZX
01:40:50 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
1.815
USD
|
-3.46%
|
|
-14.24%
|
-10.00%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
504.6
|
313
|
49.54
|
46.16
|
-
|
-
|
Enterprise Value (EV)
1 |
504.6
|
313
|
49.54
|
46.16
|
46.16
|
46.16
|
P/E ratio
|
-1.95
x
|
-4.77
x
|
-0.83
x
|
-0.74
x
|
-0.67
x
|
-0.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
451
x
|
20.6
x
|
2.03
x
|
1.86
x
|
1.73
x
|
0.71
x
|
EV / Revenue
|
451
x
|
20.6
x
|
2.03
x
|
1.86
x
|
1.73
x
|
0.71
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-22.5
x
|
-6.25
x
|
-
|
-0.65
x
|
-0.65
x
|
-0.73
x
|
FCF Yield
|
-4.45%
|
-16%
|
-
|
-153%
|
-154%
|
-136%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,894
|
24,395
|
24,526
|
24,554
|
-
|
-
|
Reference price
2 |
24.15
|
12.83
|
2.020
|
1.880
|
1.880
|
1.880
|
Announcement Date
|
3/17/22
|
3/29/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.12
|
15.22
|
24.35
|
24.8
|
26.63
|
65.38
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-111.2
|
-62.68
|
-71.93
|
-77.71
|
-89.88
|
-83.36
|
Operating Margin
|
-9,930.09%
|
-411.94%
|
-295.36%
|
-313.33%
|
-337.49%
|
-127.5%
|
Earnings before Tax (EBT)
1 |
-110.1
|
-60.51
|
-65.76
|
-74.74
|
-89.53
|
-66.71
|
Net income
1 |
-110.7
|
-60.51
|
-65.76
|
-74.74
|
-89.53
|
-63.38
|
Net margin
|
-9,887.23%
|
-397.69%
|
-270.04%
|
-301.37%
|
-336.17%
|
-96.94%
|
EPS
2 |
-12.41
|
-2.690
|
-2.440
|
-2.526
|
-2.795
|
-2.715
|
Free Cash Flow
1 |
-22.47
|
-50.08
|
-
|
-70.5
|
-71
|
-63
|
FCF margin
|
-2,006.16%
|
-329.15%
|
-
|
-284.27%
|
-266.58%
|
-96.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
3/29/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
1
|
2.307
|
3.437
|
4.245
|
5.227
|
5.867
|
6.202
|
5.959
|
6.326
|
5.353
|
6.495
|
6.778
|
6.895
|
6.675
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.16
|
-15.94
|
-13.81
|
-18.36
|
-15.04
|
-15.47
|
-16.82
|
-19.54
|
-17.85
|
-17.71
|
-19.51
|
-19.35
|
-20.29
|
-18.95
|
-20.82
|
Operating Margin
|
-
|
-1,594.5%
|
-598.79%
|
-534.19%
|
-354.2%
|
-296%
|
-286.77%
|
-315.14%
|
-299.53%
|
-280.02%
|
-364.51%
|
-297.96%
|
-299.37%
|
-274.87%
|
-311.99%
|
Earnings before Tax (EBT)
1 |
-87.09
|
-15.99
|
-13.86
|
-18.26
|
-14.47
|
-13.92
|
-15.22
|
-17.97
|
-16.3
|
-16.27
|
-18.29
|
-18.59
|
-19.6
|
-18.73
|
-20.62
|
Net income
1 |
-87.24
|
-15.99
|
-13.86
|
-18.27
|
-14.47
|
-13.91
|
-15.22
|
-17.97
|
-16.3
|
-16.27
|
-18.29
|
-18.59
|
-19.6
|
-18.73
|
-20.62
|
Net margin
|
-
|
-1,599%
|
-600.65%
|
-531.54%
|
-340.97%
|
-266.18%
|
-259.47%
|
-289.76%
|
-273.57%
|
-257.18%
|
-341.66%
|
-286.24%
|
-289.16%
|
-271.65%
|
-308.94%
|
EPS
2 |
-9.170
|
-0.7700
|
-0.6600
|
-0.8700
|
-0.6800
|
-0.4800
|
-0.5700
|
-0.6700
|
-0.6000
|
-0.6000
|
-0.6800
|
-0.6100
|
-0.5200
|
-0.4900
|
-0.7300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/17/22
|
5/12/22
|
8/10/22
|
11/9/22
|
3/29/23
|
5/10/23
|
8/9/23
|
11/8/23
|
3/13/24
|
5/8/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-22.5
|
-50.1
|
-
|
-70.5
|
-71
|
-63
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.05
|
-
|
-
|
6
|
8
|
10
|
Capex / Sales
|
4.11%
|
-
|
-
|
24.19%
|
30.04%
|
15.3%
|
Announcement Date
|
3/17/22
|
3/29/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
1.88
USD Average target price
11
USD Spread / Average Target +485.11% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.00% | 46.16M | | -2.61% | 88.47B | | +3.55% | 40.71B | | -14.04% | 32.43B | | +55.89% | 24.28B | | -16.16% | 15.52B | | -41.29% | 12.17B | | -15.45% | 12.01B | | -11.75% | 12B | | +7.87% | 8.87B |
Biopharmaceuticals
|